Published in Hum Mutat on March 16, 2015
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell (2016) 2.65
Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature (2016) 2.27
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med (2016) 2.04
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (2016) 1.95
Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy. Nature (2017) 1.44
Recurrent and functional regulatory mutations in breast cancer. Nature (2017) 1.39
Patient-derived cell models as preclinical tools for genome-directed targeted therapy. Oncotarget (2015) 1.06
Comprehensive assessment of cancer missense mutation clustering in protein structures. Proc Natl Acad Sci U S A (2015) 1.06
Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases. Cancer Discov (2015) 0.98
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov (2016) 0.98
Whole-genome mutational burden analysis of three pluripotency induction methods. Nat Commun (2016) 0.93
Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data. Genome Biol (2014) 0.92
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med (2016) 0.92
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer Discov (2017) 0.87
Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov (2016) 0.87
Smarca4 ATPase mutations disrupt direct eviction of PRC1 from chromatin. Nat Genet (2016) 0.84
Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer. Clin Cancer Res (2016) 0.81
Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White Populations. JAMA Oncol (2017) 0.81
Notch pathway activation is essential for maintenance of stem-like cells in early tongue cancer. Oncotarget (2016) 0.80
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma. Nat Commun (2016) 0.80
Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations. Oncotarget (2016) 0.79
Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the γ-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. Cold Spring Harb Mol Case Stud (2015) 0.79
Integrated genomics approach to identify biologically relevant alterations in fewer samples. BMC Genomics (2015) 0.78
Genomic evolution and chemoresistance in germ-cell tumours. Nature (2016) 0.78
Unmasking targets of antitumor immunity via high-throughput antigen profiling. Curr Opin Biotechnol (2016) 0.77
Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors. Neuro Oncol (2017) 0.77
Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma. Oncotarget (2016) 0.77
TMC-SNPdb: an Indian germline variant database derived from whole exome sequences. Database (Oxford) (2016) 0.77
TransVar: a multilevel variant annotator for precision genomics. Nat Methods (2015) 0.76
Elucidating Genomic Characteristics of Lung Cancer Progression from In Situ to Invasive Adenocarcinoma. Sci Rep (2016) 0.75
Molecular classification of tissue from a transformed non-Hogkin's lymphoma case with unexpected long-time remission. Exp Hematol Oncol (2017) 0.75
Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet (2016) 0.75
Precision medicine driven by cancer systems biology. Cancer Metastasis Rev (2017) 0.75
Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2. Nat Commun (2017) 0.75
Identification of somatic mutations using whole-exome sequencing in Korean patients with acute myeloid leukemia. BMC Med Genet (2017) 0.75
Advances in the Molecular Analysis of Soft Tissue Tumors and Clinical Implications. Surg Pathol Clin (2015) 0.75
Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract. Mod Pathol (2015) 0.75
Analysis of somatic microsatellite indels identifies driver events in human tumors. Nat Biotechnol (2017) 0.75
Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4. Clin Cancer Res (2017) 0.75
Resources for Interpreting Variants in Precision Genomic Oncology Applications. Front Oncol (2017) 0.75
The genomic dynamics during progression of lung adenocarcinomas. J Hum Genet (2017) 0.75
Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway. Oncotarget (2017) 0.75
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
A landscape of driver mutations in melanoma. Cell (2012) 12.61
High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods (2008) 12.56
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet (2010) 10.15
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A (2008) 8.08
Outcome signature genes in breast cancer: is there a unique set? Bioinformatics (2004) 7.96
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23